Doximity (DOCS) Stock Price Target Cut Due to Pharma Budget Concerns

AI Summary

Canaccord Genuity has lowered its price target for Doximity (DOCS) due to concerns regarding pharmaceutical budgets. The revised target reflects ongoing issues in the pharma sector that could impact Doximity's revenue. This adjustment signals potential challenges for DOCS as it navigates a tightening market. Analysts are closely monitoring these developments as they could influence Doximity's stock performance moving forward.